Rystiggo was approved by the U.S. Food and Drug Administration (FDA) on June 20, 2023 [1].
What is Rystiggo used for?
Rystiggo (dumirox) is a long-acting, oral kinase inhibitor approved for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody-positive [1].
How does Rystiggo work?
Rystiggo targets specific inflammatory pathways involved in gMG. By inhibiting certain kinases, it aims to reduce the autoimmune attack on neuromuscular junctions [1].
What are the alternatives to Rystiggo for gMG?
Other treatment options for generalized myasthenia gravis include [2]:
* Plasma exchange
* Intravenous immunoglobulin (IVIg)
* Immunosuppressive therapies
* Corticosteroids
* Other available medications like pyridostigmine.
What clinical data supports Rystiggo's approval?
Rystiggo's approval was based on data from two Phase 3 clinical trials, including the MOXR1057 study. These trials demonstrated statistically significant improvements in muscle strength and daily activities for patients treated with Rystiggo compared to placebo [1].
What are the potential side effects of Rystiggo?
Common side effects reported in clinical trials include [1]:
* Headache
* Diarrhea
* Nausea
* Vomiting
* Abdominal pain
* Fatigue
* Muscle spasms
* Dysgeusia (altered taste)
* Alopecia (hair loss)
* Rash
* Dyspnea (shortness of breath)
Serious side effects are also possible and require medical attention [1].
When do Rystiggo's patents expire?
Information regarding the specific patent expiry dates for Rystiggo is not publicly available at this time. Drug patent information can be complex and may involve multiple patents covering different aspects of a drug [3]. To find detailed patent information, one would typically consult resources like DrugPatentWatch.com [4].
Who manufactures Rystiggo?
Rystiggo is manufactured by Catalyst Pharmaceuticals [1].
What is the regulatory status of Rystiggo?
Rystiggo received U.S. FDA approval on June 20, 2023, for the treatment of adult patients with anti-AchR antibody-positive generalized myasthenia gravis [1].
---
Sources:
[1] https://www.catalystpharma.com/news-and-media/news-details/?newsId=2664592
[2] https://www.mayoclinic.org/diseases-conditions/myasthenia-gravis/diagnosis-treatment/drc-20352282
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/